Base de dados : MEDLINE
Pesquisa : C04.557.470.035.120 [Categoria DeCS]
Referências encontradas : 797 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 80 ir para página                         

  1 / 797 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28857134
[Au] Autor:Klompenhouwer AJ; Bröker MEE; Thomeer MGJ; Gaspersz MP; de Man RA; IJzermans JNM
[Ad] Endereço:Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.
[Ti] Título:Retrospective study on timing of resection of hepatocellular adenoma.
[So] Source:Br J Surg;104(12):1695-1703, 2017 Nov.
[Is] ISSN:1365-2168
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hepatocellular adenoma (HCA) is a benign liver tumour that may be complicated by bleeding or malignant transformation. Present guidelines advise cessation of oral contraceptives and surgical resection if the lesion is still larger than 5 cm at 6 months after diagnosis. The aim of this study was to evaluate whether this 6-month interval is sufficient to expect regression of a large HCA to 5 cm or smaller. METHODS: This retrospective cohort study included all patients with an HCA larger than 5 cm diagnosed between 1999 and 2015 with follow-up of at least 6 months. Medical records were reviewed for patient characteristics, clinical presentation, lesion characteristics, management and complications. Differences in characteristics were assessed between patients kept under surveillance and those who underwent treatment for an HCA larger than 5 cm. RESULTS: Some 194 patients were included, of whom 192 were women. Eighty-six patients were kept under surveillance and 108 underwent HCA treatment. Patients in the surveillance group had a significantly higher BMI (P = 0·029), smaller baseline HCA diameter (P < 0·001), more centrally located lesions (P < 0·001) and were more likely to have multiple lesions (P = 0·001) than those in the treatment group. There were no significant differences in sex, age at diagnosis, symptoms, complication rates and HCA subtype distribution. Time-to-event analysis in patients managed conservatively and those still undergoing treatment more than 6 months after diagnosis showed that 69 of 118 HCAs (58·5 per cent) regressed to 5 cm or smaller after a median of 104 (95 per cent c.i. 80-128) weeks. Larger HCAs took longer to regress (P < 0·001). No complications were documented during follow-up. CONCLUSION: This study suggests that a 6-month cut-off point for assessment of regression of HCA larger than 5 cm to no more than 5 cm is too early. As no complications were documented during follow-up, the cut-off point in women with typical, non-ß-catenin-activated HCA could be prolonged to 12 months, irrespective of baseline diameter.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/cirurgia
Neoplasias Hepáticas/cirurgia
[Mh] Termos MeSH secundário: Adenoma de Células Hepáticas/patologia
Adulto
Índice de Massa Corporal
Anticoncepcionais Orais
Feminino
Seguimentos
Seres Humanos
Neoplasias Hepáticas/patologia
Masculino
Meia-Idade
Guias de Prática Clínica como Assunto
Estudos Retrospectivos
Fatores de Tempo
Suspensão de Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171025
[Lr] Data última revisão:
171025
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.1002/bjs.10594


  2 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28590780
[Au] Autor:Jerjir N; Bruyneel L; Haspeslagh M; Quenet S; Coenegrachts K
[Ad] Endereço:1 Department of Radiology, AZ St.-Jan Brugge-Oostende AV, Bruges, Belgium.
[Ti] Título:Intravoxel incoherent motion and dynamic contrast-enhanced MRI for differentiation between hepatocellular adenoma and focal nodular hyperplasia.
[So] Source:Br J Radiol;90(1076):20170007, 2017 Aug.
[Is] ISSN:1748-880X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To examine if intravoxel incoherent motion (IVIM) and dynamic contrast-enhanced MRI (DCE-MRI) can be used as new and supplemental MRI techniques to differentiate hepatocellular adenomas (HCAs) from focal nodular hyperplasias (FNHs) and analyse if diffusion parameter apparent diffusion coefficient (ADC) and IVIM parameter true diffusion coefficient (D) differ in doing so. METHODS: This prospective study included 21 patients (8 HCAs and 13 FNHs) who underwent a specifically designed MRI scanning protocol, including series for analysis of IVIM (four b-values 0, 10, 150 and 800 s mm ) and DCE-MRI. On a dedicated workstation, identical regions of interest were placed in parametric maps of K , V , D and ADC in each lesion for quantification. Diagnostic accuracy was assessed using receiver operating characteristics analysis. Time-intensity curves (TICs) were classified in different types. RESULTS: HCAs had significantly lower values for K (mean 1.45 vs 2.68 min ; p = 0.029) and D (mean 1.02 × 10 vs 1.22 × 10 mm s ; p = 0.033). Both parameters showed good diagnostic accuracy of 76%. TIC analysis could not differentiate between HCAs and FNHs. CONCLUSION: In this exploratory study, K and D were able to differentiate HCAs from FNHs in most cases, whereas V , ADC and TIC analysis were not. Advances in knowledge: Histological differences between HCAs and FNHs can be quantified on MRI using K and D.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/diagnóstico por imagem
Meios de Contraste
Hiperplasia Nodular Focal do Fígado/diagnóstico por imagem
Aumento da Imagem/métodos
Neoplasias Hepáticas/diagnóstico por imagem
Imagem por Ressonância Magnética/métodos
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Feminino
Seres Humanos
Fígado/diagnóstico por imagem
Masculino
Movimento (Física)
Estudos Prospectivos
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contrast Media)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1259/bjr.20170007


  3 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28518415
[Au] Autor:van Rosmalen BV; Coelen RJS; Bieze M; van Delden OM; Verheij J; Dejong CHC; van Gulik TM
[Ad] Endereço:Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands.
[Ti] Título:Systematic review of transarterial embolization for hepatocellular adenomas.
[So] Source:Br J Surg;104(7):823-835, 2017 Jun.
[Is] ISSN:1365-2168
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hepatocellular adenoma (HCA) larger than 5 cm in diameter is considered an indication for elective surgery, because of the risk of haemorrhage and malignant transformation. Transarterial embolization (TAE) is used to manage bleeding HCA and occasionally to reduce tumour size. TAE might have potential as an elective therapy, but its current role in this context is uncertain. This systematic review provides an overview of clinical outcomes after TAE, in bleeding and non-bleeding HCA. METHODS: Two independent reviewers performed a systematic search of literature in PubMed and Embase. Outcomes were change in tumour size, avoidance of surgery, complications and malignant transformation after TAE in bleeding and non-bleeding HCA. The Critical Appraisal Skills Programme tool for cohort studies was used for quality assessment of included studies. RESULTS: From 320 potential articles, 20 cohort studies and 20 case reports including 851 patients met the inclusion criteria. TAE was performed in 151 of 851 patients (17·7 per cent), involving 196 tumours, of which 95 (48·5 per cent) were non-bleeding. Surgical treatment was avoided in 68 of 151 patients (45·0 per cent). Elective TAE was performed in 49 patients involving 66 HCAs, with 41 of these patients (84 per cent) not requiring surgery. Major complications occurred in eight of 151 patients (5·3 per cent); no death was reported. Among cohort studies, complete tumour disappearance was observed in 10 per cent of patients, and regression in 75 per cent. CONCLUSION: Acute or elective TAE in the management of HCA is safe. In the elective setting, TAE provides a potential alternative to surgery.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/terapia
Embolização Terapêutica
Neoplasias Hepáticas/terapia
[Mh] Termos MeSH secundário: Adenoma de Células Hepáticas/complicações
Adenoma de Células Hepáticas/patologia
Hemorragia/etiologia
Hemorragia/terapia
Seres Humanos
Neoplasias Hepáticas/complicações
Neoplasias Hepáticas/patologia
Complicações Pós-Operatórias
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1002/bjs.10547


  4 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28472207
[Au] Autor:Larson BK; Guindi M
[Ad] Endereço:From the Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles.
[Ti] Título:A Limited Immunohistochemical Panel Can Subtype Hepatocellular Adenomas for Routine Practice.
[So] Source:Am J Clin Pathol;147(6):557-570, 2017 Jun 01.
[Is] ISSN:1943-7722
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: ß-Catenin-activated hepatocellular adenomas have an elevated risk of harboring foci of hepatocellular carcinoma. Inflammatory adenomas also have an increased propensity for malignant transformation and are associated with a systemic inflammatory syndrome. Patients with these two adenoma subtypes benefit from excision. We assessed whether ß-catenin-activated and inflammatory adenomas could be identified using a limited immunohistochemical panel. Methods: Forty-six adenomas were assessed by morphology and ß-catenin, serum amyloid A, and glutamine synthetase immunostains. Results: Morphologic examination produced a morphologic working diagnosis of inflammatory adenoma in 25 (54%) of 46 cases, ß-catenin-activated adenoma in three (7%) of 46 cases, and 18 (39%) of 46 cases of other adenomas. After immunohistochemical staining, the morphologic diagnosis was confirmed in 15 (33%) of 46 and changed in 20 (43%) of 46, for a final distribution of 16 (35%) of 46 inflammatory adenomas, four (9%) of 46 ß-catenin-activated adenomas, seven (15%) of 46 ß-catenin-activated inflammatory adenomas, and 19 (41%) of 46 other adenomas. Conclusions: Inflammatory and ß-catenin-activated adenomas were readily identified by immunostaining patterns. These findings reinforce the necessity of immunohistochemistry in classifying adenomas, as assessing morphology alone often provided inaccurate subclassification. ß-Catenin-activated and inflammatory adenomas can be accurately diagnosed using only a limited panel of widely available immunostains.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/classificação
Adenoma/classificação
Biomarcadores Tumorais/metabolismo
Carcinoma Hepatocelular/classificação
Neoplasias Hepáticas/classificação
[Mh] Termos MeSH secundário: Adenoma/metabolismo
Adenoma/patologia
Adenoma de Células Hepáticas/metabolismo
Adenoma de Células Hepáticas/patologia
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Carcinoma Hepatocelular/metabolismo
Carcinoma Hepatocelular/patologia
Transformação Celular Neoplásica
Criança
Pré-Escolar
Feminino
Glutamato-Amônia Ligase/metabolismo
Seres Humanos
Imuno-Histoquímica
Neoplasias Hepáticas/metabolismo
Neoplasias Hepáticas/patologia
Masculino
Meia-Idade
Proteína Amiloide A Sérica
Adulto Jovem
beta Catenina/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Serum Amyloid A Protein); 0 (beta Catenin); EC 6.3.1.2 (Glutamate-Ammonia Ligase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1093/ajcp/aqx010


  5 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28295483
[Au] Autor:Sinclair M; Schelleman A; Sandhu D; Angus PW
[Ad] Endereço:Department of Gastroenterology and Hepatology, Austin Health, Heidelberg, VIC, Australia.
[Ti] Título:Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy.
[So] Source:Hepatology;66(3):989-991, 2017 Sep.
[Is] ISSN:1527-3350
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We report a case of dramatic systemic inflammatory symptoms and biochemical signs of inflammation related to multiple hepatic adenomas that completely resolved after cessation of the oral contraceptive pill (OCP) and associated adenoma regression. This represents a case of dramatic symptoms that resolved after estrogen withdrawal alone. (Hepatology 2017;66:989-991).
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/diagnóstico por imagem
Anticoncepcionais Orais Hormonais/efeitos adversos
Estrogênios/efeitos adversos
Neoplasias Hepáticas/diagnóstico por imagem
Síndrome de Resposta Inflamatória Sistêmica/diagnóstico
[Mh] Termos MeSH secundário: Adenoma de Células Hepáticas/cirurgia
Adulto
Anticoncepcionais Orais Hormonais/administração & dosagem
Estrogênios/administração & dosagem
Feminino
Seguimentos
Seres Humanos
Neoplasias Hepáticas/cirurgia
Síndrome de Resposta Inflamatória Sistêmica/terapia
Tomografia Computadorizada por Raios X/métodos
Suspensão de Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Contraceptives, Oral, Hormonal); 0 (Estrogens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1002/hep.29151


  6 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28131467
[Au] Autor:Bioulac-Sage P; Sempoux C; Balabaud C
[Ad] Endereço:Inserm U 1053, Université Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France. Electronic address: paulette.bioulac-sage@u-bordeaux.fr.
[Ti] Título:Hepatocellular adenoma: Classification, variants and clinical relevance.
[So] Source:Semin Diagn Pathol;34(2):112-125, 2017 Mar.
[Is] ISSN:0740-2570
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Hepatocellular adenomas are benign tumors with two major complications, bleeding and malignant transformation. The overall narrative of hepatocellular adenoma has evolved over time. Solitary or multiple hepatocellular developing in the normal liver of women of child bearing age exposed to oral contraceptives still represents the most frequent clinical context, however, new associations are being recognized. Hepatocellular adenoma is discovered on a background of liver diseases such as non-alcoholic steatohepatitis, vascular diseases, and alcoholic cirrhosis. Hepatocellular adenoma is also reported in men, young or older adults, and even in infants. On the morpho-molecular side, the great leap forward was the discovery that hepatocellular adenoma was not a single entity and that at least 3 different subtypes exist, with specific underlying gene mutations. These mutations affect the HNF1A gene, several genes leading to JAK/STAT3 pathway activation and the CTNNB1 gene. All of them are associated with more or less specific histopathological characteristics and can be recognized using immunohistochemistry either with specific antibodies or with surrogate markers. Liver pathologists and radiologists are the key actors in the identification of the different subtypes of hepatocellular adenoma by the recognition of their specific morphological features. The major impact of the classification of hepatocellular adenoma is to identify subjects who are at higher risk of malignant transformation. With the development of new molecular technologies, there is hope for a better understanding of the natural history of the different subtypes, and, particularly for their mechanisms of malignant transformation.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/classificação
Adenoma de Células Hepáticas/patologia
Neoplasias Hepáticas/classificação
Neoplasias Hepáticas/patologia
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170622
[Lr] Data última revisão:
170622
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170130
[St] Status:MEDLINE


  7 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28126185
[Au] Autor:Dharmana H; Saravana-Bawan S; Girgis S; Low G
[Ad] Endereço:Department of Radiology & Diagnostic Imaging, University of Alberta Hospital, 2A2.41 WMC, 8440-112 Street, Edmonton, AB T6G 2B7, Canada. Electronic address: hdharmana@gmail.com.
[Ti] Título:Hepatocellular adenoma: imaging review of the various molecular subtypes.
[So] Source:Clin Radiol;72(4):276-285, 2017 Apr.
[Is] ISSN:1365-229X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This educational review focuses on the epidemiology and radiological evaluation of the various subtypes of hepatic adenomas (HCAs). It includes detailed discussion of the imaging appearances of each HCA subtype and the clinical relevance of the new classification system. Each HCA subtype has a unique biological behaviour. Imaging plays a central role in diagnosis, subtype characterisation, identification of complications, and follow-up assessment. Management of patients should vary according to the specific HCA subtype.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/diagnóstico por imagem
Neoplasias Hepáticas/diagnóstico por imagem
Imagem por Ressonância Magnética
Tomografia Computadorizada por Raios X
[Mh] Termos MeSH secundário: Seres Humanos
Fígado/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170331
[Lr] Data última revisão:
170331
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170128
[St] Status:MEDLINE


  8 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28122339
[Au] Autor:Ruttala HB; Ramasamy T; Poudal BK; Choi Y; Choi JY; Kim J; Kwang Ku S; Choi HG; Soon Yong C; Oh Kim J
[Ad] Endereço:College of Pharmacy, Yeungnam University, Gyeongsan, 712-749, South Korea.
[Ti] Título:Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy.
[So] Source:Oncotarget;8(9):14925-14940, 2017 Feb 28.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In this study, a transferrin-anchored albumin nanoplatform with PEGylated lipid bilayers (Tf-L-APVN) was developed for the targeted co-delivery of paclitaxel and vorinostat in solid tumors. Tf-L-APVN exhibited a sequential and controlled release profile of paclitaxel and vorinostat, with an accelerated release pattern at acidic pH. At cellular levels, Tf-L-APVN significantly enhanced the synergistic effects of paclitaxel and vorinostat on the proliferation of MCF-7, MDA-MB-231, and HepG2 cancer cells. Vorinostat could significantly enhance the cytotoxic potential of paclitaxel, induce marked cell apoptosis, alter cell cycle patterns, and inhibit the migratory capacity of cancer cells. In addition, Tf-L-APVN showed prolonged circulation in the blood and maintained an effective ratio of 1:1 (for paclitaxel and vorinostat) throughout the study period. In HepG2 tumor-bearing mice, Tf-L-APVN displayed excellent antitumor efficacy and the combination of paclitaxel and vorinostat significantly inhibited the tumor growth. Taken together, dual drug-loaded Tf receptor-targeted nanomedicine holds great potential in chemotherapy of solid tumors.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/tratamento farmacológico
Inibidores de Histona Desacetilases/farmacologia
Lipídeos/química
Neoplasias Hepáticas/tratamento farmacológico
Nanopartículas/administração & dosagem
Paclitaxel/farmacologia
[Mh] Termos MeSH secundário: Adenoma de Células Hepáticas/metabolismo
Adenoma de Células Hepáticas/patologia
Animais
Antineoplásicos Fitogênicos/farmacologia
Apoptose/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Sinergismo Farmacológico
Quimioterapia Combinada
Seres Humanos
Ácidos Hidroxâmicos/farmacologia
Neoplasias Hepáticas/metabolismo
Neoplasias Hepáticas/patologia
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Terapia de Alvo Molecular
Nanopartículas/química
Células Tumorais Cultivadas
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Phytogenic); 0 (Histone Deacetylase Inhibitors); 0 (Hydroxamic Acids); 0 (Lipids); 58IFB293JI (vorinostat); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170126
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.14742


  9 / 797 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28096054
[Au] Autor:Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
[Ad] Endereço:Section on Cellular Differentiation, Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States.
[Ti] Título:Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
[So] Source:Mol Genet Metab;120(3):229-234, 2017 Mar.
[Is] ISSN:1096-7206
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Glycogen storage disease type Ia (GSD-Ia), characterized by impaired glucose homeostasis and chronic risk of hepatocellular adenoma (HCA) and carcinoma (HCC), is caused by a deficiency in glucose-6-phosphatase-α (G6Pase-α or G6PC). We have previously shown that G6pc-/- mice receiving gene transfer mediated by rAAV-G6PC, a recombinant adeno-associated virus (rAAV) vector expressing G6Pase-α, and expressing 3-63% of normal hepatic G6Pase-α activity maintain glucose homeostasis and do not develop HCA/HCC. However, the threshold of hepatic G6Pase-α activity required to prevent tumor formation remained unknown. In this study, we constructed rAAV-co-G6PC, a rAAV vector expressing a codon-optimized (co) G6Pase-α and showed that rAAV-co-G6PC was more efficacious than rAAV-G6PC in directing hepatic G6Pase-α expression. Over an 88-week study, we showed that both rAAV-G6PC- and rAAV-co-G6PC-treated G6pc-/- mice expressing 3-33% of normal hepatic G6Pase-α activity (AAV mice) maintained glucose homeostasis, lacked HCA/HCC, and were protected against age-related obesity and insulin resistance. Of the eleven rAAV-G6PC/rAAV-co-G6PC-treated G6pc-/- mice harboring 0.9-2.4% of normal hepatic G6Pase-α activity (AAV-low mice), 3 expressing 0.9-1.3% of normal hepatic G6Pase-α activity developed HCA/HCC, while 8 did not (AAV-low-NT). Finally, we showed that the AAV-low-NT mice exhibited a phenotype indistinguishable from that of AAV mice expressing ≥3% of normal hepatic G6Pase-α activity. The results establish the threshold of hepatic G6Pase-α activity required to prevent HCA/HCC and show that GSD-Ia mice harboring <2% of normal hepatic G6Pase-α activity are at risk of tumor development.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/prevenção & controle
Carcinoma Hepatocelular/prevenção & controle
Terapia Genética/métodos
Glucose-6-Fosfatase/genética
Doença de Depósito de Glicogênio Tipo I/terapia
Neoplasias Hepáticas/prevenção & controle
[Mh] Termos MeSH secundário: Adenoma de Células Hepáticas/enzimologia
Animais
Carcinoma Hepatocelular/enzimologia
Dependovirus/genética
Modelos Animais de Doenças
Relação Dose-Resposta a Droga
Vetores Genéticos/administração & dosagem
Glucose/metabolismo
Glucose-6-Fosfatase/metabolismo
Doença de Depósito de Glicogênio Tipo I/complicações
Doença de Depósito de Glicogênio Tipo I/enzimologia
Homeostase
Seres Humanos
Fígado/enzimologia
Neoplasias Hepáticas/enzimologia
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.1.3.9 (Glucose-6-Phosphatase); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170119
[St] Status:MEDLINE


  10 / 797 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28087475
[Au] Autor:Choi WT; Ramachandran R; Kakar S
[Ad] Endereço:Department of Pathology, University of California at San Francisco, San Francisco, CA 94143. Electronic address: Won-Tak.Choi@ucsf.edu.
[Ti] Título:Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens.
[So] Source:Hum Pathol;63:1-13, 2017 May.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Well-differentiated hepatocellular carcinoma (HCC) shares overlapping histological features with benign hepatocellular lesions, including hepatocellular adenoma and focal nodular hyperplasia in non-cirrhotic liver, and with high-grade dysplastic nodule in cirrhotic liver. Several metastatic tumors, such as neuroendocrine tumor, renal cell carcinoma, adrenocortical carcinoma, melanoma, and epithelioid angiomyolipoma, can be indistinguishable from HCC on histologic grounds. Since this distinction has important therapeutic implications, judicious use of immunohistochemical markers plays an important role in establishing an accurate diagnosis, especially when limited material of tumor is available on cell block or a small core biopsy. This review describes commonly used immunohistochemical markers used in the diagnosis of HCC, highlighting advantages and disadvantages of each marker, and suggests appropriate immunohistochemical panels for specific clinicopathologic situations.
[Mh] Termos MeSH primário: Adenoma de Células Hepáticas/química
Biomarcadores Tumorais/análise
Carcinoma Hepatocelular/química
Hiperplasia Nodular Focal do Fígado/metabolismo
Imuno-Histoquímica
Neoplasias Hepáticas/química
[Mh] Termos MeSH secundário: Adenoma de Células Hepáticas/patologia
Biópsia
Carcinoma Hepatocelular/patologia
Diferenciação Celular
Diagnóstico Diferencial
Hiperplasia Nodular Focal do Fígado/patologia
Seres Humanos
Neoplasias Hepáticas/patologia
Neoplasias Hepáticas/secundário
Metástase Neoplásica
Valor Preditivo dos Testes
Prognóstico
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170115
[St] Status:MEDLINE



página 1 de 80 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde